Archive
Every story, newest first.
Saturday, November 7, 2026
Infrastructure
WSP Global's backlog reached a record 20.3 billion Canadian dollars at September 25, 2026, up 23.5 percent in a year, even as its chief executive warned that United States funding reviews are stretching the time between award and start of work.
Infrastructure
Walleye Capital plans to return about 2 billion dollars to clients and is cutting back its internal equity long-short business after losing 5.9 percent in October, its worst month since March 2020.
Rates
Bank of Japan Governor Kazuo Ueda told the IMF's Camdessus lecture on Friday that Japan's current account surplus, still 2 to 4 percent of GDP, is now carried by overseas investment income above 6 percent of GDP rather than by exports, and offered no new signal on monetary policy.
Rates
Czech Prime Minister Andrej Babis was reported to have called the central bank's latest rate increase scandalous, Paraguay's Ueno Bank depositors began receiving guarantee transfers, and the Bank of Canada's summary of deliberations is due on November 10.
Rates
San Francisco Fed President Mary Daly said on Friday that further rate increases are likely to be needed, hours after October payrolls rose 165,000, while New York Fed President John Williams urged gathering more information and the White House argued the jobs report is no reason to hike.
Rates
Euro area governments closed nominations for the ECB presidency on Friday with only two candidates, Spain's Pablo Hernandez de Cos and the Netherlands' Klaas Knot, to succeed Christine Lagarde from February.
Rates
The yield on CoreWeave's 9.625 percent notes due 2032 climbed above 16 percent on Friday, CNBC reported, and the cost of insuring its debt spiked past 1,289 basis points on Thursday before easing to about 1,155, as credit markets charge AI data centre builders more to borrow.
Life Sciences
In a Phase 1/2 study, Immunocore's brenetafusp combined with Kimmtrak produced a 29 percent response rate and an estimated 70 percent two year survival rate in 17 evaluable first line patients with metastatic uveal melanoma.
Life Sciences
Oregon, Minnesota, New Mexico and Washington sued the Trump administration on November 5 to block Medicaid work requirements that take effect on January 1, 2027, arguing the conditions exceed Congress's spending power.
Life Sciences
Alnylam's chief commercial officer is leaving amid Amvuttra sales concerns, ANI Pharmaceuticals offered 560 million dollars for Sweden's Egetis Therapeutics, and Ultragenyx will cut 1,000 jobs after its Angelman gene therapy failed.